Under various circumstances, the Food and Drug Administration may require a drug maker to run a post-marketing study, but a large percentage of these studies are still pending, according to the latest agency analysis.
As of the end of fiscal year 2016, 86 percent of required studies were still pending, which meant they were not yet under way. An average of 261 post-marketing requirements were made each year since fiscal year 2010, and most that were established several years ago were since fulfilled or released. Of the required studies pending as of September 30, 2016, 83 percent were created within the past three years, according to the FDA analysis.
About the Author Reprints
